Adjusted analysis revealed no difference in time to first CV event if MRA was added/intensified in those with elevated galectin-@ ( hazard ratio @ , @ % CI @-@ @ , P = @ ) ; similarly , cumulative MRA dose was not a specific predictor of benefit .